City of Hope vice provost to focus on faculty growth initiatives

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Arti Hurria, City of Hope’s new vice provost, plans to focus on faculty growth and development, including fostering faculty career development and ensuring more diverse voices are represented.

Hurria, a geriatrician and oncologist who has been at City of Hope for 10 years, is also its director of Cancer and Aging Research Program. As vice provost, she will have primary oversight of academic and faculty affairs for physicians in the clinical professor series.

She will support City of Hope’s mission to increase the diversity of clinical faculty, and is responsible for designing, implementing and assessing various programs to address faculty diversity, recruitment, retention and advancement.

Hurria’s goals toward those ends include developing pilot grant awards for junior faculty, organizing a regular meeting for women leaders in the oncology field to share experiences and advice with female faculty, informing faculty of career development opportunities outside City of Hope, and supporting diversity at all levels.

“As the daughter of Indian immigrants and doctors, I am particularly passionate about ensuring that diverse voices are represented at the table,” Hurria said.

“One of the opportunities that truly helped me grow was serving as chair of the ASCO Professional Development Committee, where I was able to strategically plan professional development activities for members. I realized just how many opportunities there are within our own field to help foster the careers of individuals within our own profession. As vice provost, I will work to bring those opportunities to City of Hope and develop programs that can foster the career development for all of our faculty members.”

Table of Contents

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login